Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
Cancer May 14, 2018
Naqvi K, et al. - Researchers evaluated the efficacy and safety of a lower dose of dasatinib (50 mg daily), a BCR-ABL1 and Src family tyrosine kinase inhibitor, in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), since myelosuppression and pleural effusions are associated with the approved 100 mg daily oral dose. At 3 months, the observed rates of patients achieving BCR-ABL1 transcript levels ≤ 10% and ≤ 1% by the International Standard were 93% and 72%, respectively. At 12 months, a major molecular response, a molecular response with a 4.0-log reduction, and a molecular response with a 4.5-log reduction, respectively, was achieved by 79%, 71%, and 46% of the patients. Overall, dasatinib 50 mg daily showed activity as well as good tolerability in patients with newly diagnosed CML-CP.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries